Jyong Biotech MENS
NASDAQ MENS
$1.74 -0.15 (-7.94%)
At close: Oct 22, 2026 · 4:00 PM EDT

Jyong Biotech (MENS) Construction in Progress (2024 - 2025)

Updated

Jyong Biotech (MENS) posted Construction in Progress of $140,000 for the quarter ended Dec 31, 2025, up 3.7% from $135,000 a year earlier.

Analysis

Jyong Biotech (MENS) Construction in Progress (2024 - 2025) Analysis & Trends

  • In prior years, Jyong Biotech's Construction in Progress was $135,000 in the year ended Dec 31, 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn -
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn -
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn -
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn -
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn -
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn -
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn -
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn -
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn -
10 Jyong Biotech 132.29 Mn 131.11 Mn - 140,000.00
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 140,000.00
Dec 31, 2024 135,000.00
API Access

Jyong Biotech Construction in Progress API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=construction-in-progress&ticker=MENS&period=max&api_key=YOUR_API_KEY